anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Congenital coronary artery anomalies (CCAA) represent one of the most challenging conditions as their clinical presentation may range from sudden cardiac death to a complete subclinical form. The aim of the present study was to evaluate the diagnostic and prognostic role of cardiac CT (CCT) evaluation in patients with CCAA, focusing on anomalies of origin.
MATERIAL AND METHODS: The present is a retrospective analysis of a prospective clinical registry including a consecutive cohort of patients who underwent clinically indicated CCT from January 2007 to October 2015 for suspected but unknown coronary artery disease (CAD) and were diagnosed for having a congenital coronary abnormality compared to a control group matched for age, sex and segment stenosis score (SSS). Dedicated analysis of all CCT was performed for the present study and only coronary anomalies of origin were considered and included in the study. Two different composite end-points were identified for the present analysis: major cardiovascular events (MACE) and all-cause of death.
RESULTS: Among the 81 patients with CCAAs enrolled the most frequent anomaly was left main artery absence, which was identified in 41 individuals (50.6%). Forty-five subjects (55.5%) have an anomalous origin of the coronary artery from a different sinus of Valsalva and 45 subjects had also an anomalous course with the retro-aortic being the most common (32%). Eleven participants (13.6%) displayed also an intramural segment, while 10 (10.3%) had a slit-like ostial morphology. At multivariate analysis CT identification of ARCA, anomalous inter-arterial course and abnormal ostial morphology were significantly associated with MACE even when adjusted for age and SSS, without any differences in all-cause mortality between the two groups (6.2% vs 2.4% p ​= ​0.2478).
CONCLUSION: The result of the present study is that CCT can be successfully used to define the anatomy and features of CAA. It suggested that in middle-aged patients, the identification of high risk characteristics at CT may have a prognostic value in term of cardiovascular events occurrence at follow-up even if the rate of events strictly linked to CCAA is low.
In the past two decades overweight and obesity rates in children (ages 2-19) have risen from 5% to 17%, with toddlers (ages 2-5) at 10%. Among children and adolescents the consumption of low-energy-dense foods, such as fruit and vegetables (F\&Vs), remain below current recommendations. Therefore, strategies to increase low-energy-dense F\&V intake and decrease high-energy-dense food intake aimed at young children are essential. Antecedents, or cues, can trigger eating. Therefore, manipulating food presentation can be utilized to produce certain behaviors. Dietary variety and course sequence are two examples of this relationship. It has been well established that high dietary variety leads to greater consumption patterns compared to low DV diets in adults. High DV has only been tested with problematic foods, and not with the goal of increasing F\&V intake. Additionally, serving a first course meal can act as a preload to decrease intake of the second course entrée. Dietary variety and course sequence manipulations have been experimentally tested with caloric intake goals but never with the goal of increasing F\&V intake. Therefore, the purpose of this study is to determine the extent to which manipulation of dietary variety and course sequence affects fruit intake and overall energy intake in preschool-aged children.
The patients in the intervention group will be called by the researcher within 3-7 days after discharge for the purpose of getting to know each other. The researcher will inform the participants/relatives about the purpose of the study and the procedures to be performed. The date and time for the next call will be given and the next phone call will be planned. The researcher will inform the patients/relatives about the materials sent. During the phone call, any questions the patient has about their illness, medications, or oxygen concentrator will be answered by the researcher. Then, the patient will be asked whether they have been to the hospital after being discharged and this self-reported information will be recorded on the prepared hospital application form. If they have applied to the hospital, the department(s) will be asked and noted. At the end of the phone call, the time and day of the next call will be planned with the patient/relatives. The second phone call will be made by the researcher within 3 months after discharge to the patients in the intervention group and the date and time of the phone call will be planned after the approval of the researcher and the patient/relatives and the call plan will be made. During the phone call, the researcher will first introduce himself/herself and briefly explain why the phone call is being made. During the phone call, any questions the patient may have about his/her illness, medications, or oxygen concentrator will be answered by the researcher. Then, after the patient is discharged, the patient's hospital application will be asked and the answers received based on self-reporting will be written on the hospital application form. If there is a hospital application, the department/departments will be asked and noted. 5 minutes of the phone call will include introductions and general topics about the illness, the second 5 minutes will answer any questions the patient/relatives may have, and the last 5 minutes will end with the researcher providing consultancy services on what needs to be done in the future. Care will be taken not to exceed 20 minutes. At the end of the call, the date and time of the last call will be determined by talking to the patient/relative. In the phone call in the third month, the mMRC dyspnea scale and the St George Respiratory Questionnaire (Quality of Life Scale) and Hospital Application Form interim measurements will be collected by a researcher outside the study.
<P>PROBLEM TO BE SOLVED: To provide a prophylactic/ameliorating agent for cerebrovascular dementia, a prophylactic/ameliorating food or beverage or a food or beverage auxiliary food which are each safely useable over a long period.  <P>SOLUTION: The present invention provides a prophylactic/ameliorating agent for cerebrovascular dementia, a prophylactic/ameliorating food and beverage, a food or beverage or an auxiliary food each containing citric acid and/or isocitric acid as an active ingredient. The citric acid and/or the isocitric acid exhibits activity suppressing neurocyte death by zinc deeply involved in cerebrovascular dementia. The citric acid and/or the isocitric acid may be a synthetic product or natural product and preferably is derived from fruits and e. g. juices or their processed foods of Mangifera indica fruit, Citrus tamurana, Citrus junos Tanaka Silbes, Citrus sphaerocarpa Hort. ex Tanaka, Citrus limon, Citrus junos, Citrus sudachi Hort. ex Shirai or the like can be used as the citric acid and/or the isocitric acid.  <P>COPYRIGHT: (C)2009,JPO&INPIT
1. A DNA whose nucleotide sequence is represented by the base sequence No. from 1 to 10877 shown in SEQ ID NO. 1 of the Sequence Listing that encodes a human bone morphogenetic protein-7 promoter region, or a fragment thereof. 2. A method for preparing the DNA as claimed in claim 1 comprising the steps of: (1) digestion of a human placenta genomic DNA with a HindIII restriction enzyme, (2) isolation a DNA fragment about 11 kb by electrophoresis treated with HindIII mixture in agarose gel, (3) cloning of the isolated DNA fragment digested with HindIII into a λ phage vector λ DASH II treated with the same enzyme, (4) packaging of said vector into the phage, (5) establishment of genomic DNA library by infecting Escherichia coli with the phage, (6) screening by PCR, by using PCR primers shown in SEQ ID NO. 2 and 3 of the Sequence Listing, corresponding to exon region of human BMP-7 gene, (7) subcloning a gene fragment to obtain finally 5' upstream region (10.8 kb) of human BMP-7 gene into a plasmid vector to prepare DNA according to claim 1. 3. A recombinant expression vector characterized by integration of DNA into a region upstream reporter gene according to claim 1.
Post transfemoral coronary angiography (TFCA) may be associated with complications such as oozing, bleeding, ecchymosis, hematoma, and back pain. As a result, nursing practice must be geared toward enhancing patient safety post-transfemoral coronary angiography procedure. This study aimed to assess the effect of position change and back massage versus early ambulation on post transfemoral coronary angiography complications. A quasi-experimental research design was used to conduct this study at the Coronary Care Unit of the selected university hospital in Egypt. A convenience sample of 185 patients undergoing transfemoral coronary angiography was included in the study during the first 6 hours post-transfemoral coronary angiography and randomly assigned to two groups: 92 patients received position change and back massage (PCBM group), and 93 patients underwent early ambulation after the first 3 hours post-transfemoral coronary angiography (EA group). The used tool was "Post Transfemoral Coronary Angiography Complication Assessment".
The arrangement (10) e.g. pen injecting aid, has an adjusting unit for adjusting application quantity, and a storage provided for storing the application quantity. A recording unit records date and/or time, where the date and/or time are storable together with the adjusted dose. An adapter (27) includes a threaded rod (38) for an advancement of a syringe plunger (24) to different cartridges (20). A covering (28) is open on one side for receiving the cartridge, and includes an aperture at the other end for rotationally secure receivable of the threaded rod. An independent claim is also included for a network for transmission, storage and processing of data concerning the dosage of medicines.
FIELD: chemistry of heterocyclic compounds, biochemistry, pharmacy. SUBSTANCE: invention relates to new heterocyclic compounds of the general formula (I-a)   where sign * means carbon atom labeled as * and represents asymmetric carbon atom; A and B are similar or different and each represents lower alkylene group optionally substituted with oxo-group; D represents heteromonocyclic group of the formula (a)   wherein D 1  represents methylene or ethylene group and these groups are optionally substituted with oxo-group; ring G represents 5- or 6-membered saturated or unsaturated heteromonocyclic group optionally containing nitrogen atom; indicated heterocyclic group can be optionally substituted with substituent T 1  wherein T 1  represents 1-3 similar or different groups taken among: (i) oxo-group; (ii) lower alkyl group; R 1  and R 2  are similar or different and each represents lower alkyl group; R 3  and R 4  differ of one another and each represents hydrogen atom or hydroxy-group, or both in common form oxo-group; R 5  represents group of the formula (b)  ; X 1  and X 2  are halogen atom; Y 1  is halogen atom, lower alkoxycarbonyl group, aralkylaminocarbonyl group or group of the formula c)   wherein U is oxygen atom; Q represents unsubstituted ortho-phenylene group; n = 0 or 1; m = 0; or their esters, or salts. Inhibitor of human neutrophile elastase comprises compound of the formula (I-b)   as an active component. Invention relates also to pharmaceutical composition eliciting inhibitory effect with respect to human neutrophile elastase comprising compound of the formula (I-b) as an active component or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier or excipient. Invention provides preparing heterocyclic compounds eliciting inhibitory effect on activity of human neutrophile elastase. EFFECT: valuable medicinal and biochemical properties of compounds. 8 cl, 9 tbl
The present invention provides C. neoformans genes that are essential and are potential targets for drug screening. The nucleotide sequence of the target genes can be used for various drug discovery purposes, such as expression of the recombinant protein, hybridization assay and construction of nucleic acid arrays. The uses of proteins encoded by the essential genes, and genetically engineered cells comprising modified alleles of essential genes in various screening methods are also encompassed by the invention. The present invention also provides methods and compositions that enable the experimental determination as to whether any gene in the genome of Cryptococcus neoformans  is essential, and whether that gene is required for virulence or pathogenicity. The identification of essential genes and those genes critical to the development of virulent infections, provides a basis for the development of screens for new drugs against $i(C. neoformans.)
BACKGROUND: Dysregulation of vascular smooth muscle cell (VSMC) function leads to a variety of diseases such as atherosclerosis and hyperplasia after injury. However, antiproliferative drug targeting VSMC exhibits poor specificity. Therefore, there is an urgent to develop highly specific antiproliferative drugs to prevention and treatment VSMC dedifferentiation associated arteriosclerosis. Kanglexin (KLX), a new anthraquinone compound designed by our team, has potential to regulate VSMC phenotype according to the physicochemical properties.
PURPOSE: This project aims to evaluate the therapeutic role of KLX in VSMC dedifferentiation and atherosclerosis, neointimal formation and illustrates the underlying molecular mechanism.
METHODS: In vivo, the ApoE-/- mice were fed with high-fat diet (HFD) for a duration of 13 weeks to establish the atherosclerotic model. And rat carotid artery injury model was performed to establish the neointimal formation model. In vitro, PDGF-BB was used to induce VSMC dedifferentiation.
RESULTS: We found that KLX ameliorated the atherosclerotic progression including atherosclerotic lesion formation, lipid deposition and collagen deposition in aorta and aortic sinus in atherosclerotic mouse model. In addition, The administration of KLX effectively ameliorated neointimal formation in the carotid artery following balloon injury in SD rats. The findings derived from molecular docking and surface plasmon resonance (SPR) experiments unequivocally demonstrate that KLX had potential to bind PDGFR-β. Mechanism research work proved that KLX prevented VSMC proliferation, migration and dedifferentiation via activating the PDGFR-β-MEK -ERK-ELK-1/KLF4 signaling pathway.
CONCLUSION: Collectively, we demonstrated that KLX effectively attenuated the progression of atherosclerosis in ApoE-/- mice and carotid arterial neointimal formation in SD rats by inhibiting VSMC phenotypic conversion via PDGFR-β-MEK-ERK-ELK-1/KLF4 signaling. KLX exhibits promising potential as a viable therapeutic agent for the treatment of VSMC phenotype conversion associated arteriosclerosis.
Surface micromachining and bulk micromachining are employed for realizing a porous membrane with bulk support for a microparticle fiter. The filter is sufficiently sturdy to allow for easy handling. It may be used as a diffusion barrier and under high pressures. The disclosed fabrication method is simple, reliable, and integrated-circuit compatible, and thus amenable to mass production. Electronic circuitry may be integrated on the filter surface, as may be desired for several purposes, such as fluid characterization, filter self-cleaning, or charging of the filter surfaces. Methods are shown for the realization of biological containment capsules based on this microfilter.
A safe and trackable pill dispenser assembly, a system for tracking and administering medications using the pill dispenser assembly, and related methods are presented herein. The pill dispenser assembly may include a tamper resistant cartridge and a smart pill dispensing portion. The pill dispensing portion of the pill dispenser assembly may be configured to authenticate a patient to the pill dispenser assembly and dispense medication according to a prescription accessible to the dispenser portion. The patient can separate the cartridge from the dispenser portion at the end of the prescription period and match a new cartridge with the dispenser portion at a new prescription period. The cartridges may be filled and delivered to the patient by a pharmacy and/or pharmaceutical partner. The cartridge is capable of inhibiting extraction of the medicament when not matched to the dispensing portion.
The invention relates to a novel method for preparing polysaccharide-polypeptide nano-granules with anti-oxidative activity. The nano-granules are applied to the medicine and food industry and are taken as an oral delivery carrier of a medicine and a food functional factor. The gallic acid is grafted to a chitosan molecular chain through the mediation of carbodiimide and hydroxybenzotriazole. The novel nano-granules are prepared by self-assembly between the gallic acid grafted chitosan and the casein phosphopeptides molecule. The research through a dipheny pierylhydrazine (DPPH) free radical method and a beta-carotene-linoleic acid method shows that the novel nano-granules have strong anti-oxidative activity. The process method provided by the invention has the advantages of mild reaction condition, low cost and environment protection. The prepared polymer nano-granules have anti-oxidative activity and wide application prospect.
BACKGROUND: Post-COVID-19 condition (PCC), also known as "long COVID," is characterized by persistent symptoms, negatively affecting the well-being of individuals with PCC. Anhedonia (i.e. reduced capacity for pleasure) and compromised psychosocial functioning are notable symptoms in those with PCC. We aimed to provide insights to understand the effects of anhedonia and impaired psychosocial functioning of individuals with PCC.
METHODS: This post-hoc analysis used data from an 8-week, double-blind, randomized, placebo-controlled trial which evaluated vortioxetine for cognitive deficits in individuals with PCC (Clinicaltrials.gov Identifier: NCT05047952). A total of 147 eligible participants were randomly assigned to receive vortioxetine or matching placebo over eight weeks of double-blind treatment. Our study investigated the relationship between anhedonia, assessed by the Snaith-Hamilton Pleasure Scale (SHAPS), and psychosocial functioning, measured with the Post-COVID Functional Status (PCFS) scale. The analysis was conducted using a generalized linear model, with adjustments for relevant covariates such as age, sex, education, suspected versus confirmed COVID diagnosis, MDD diagnosis, and alcohol consumption.
RESULTS: Of the 147 participants, 143 participants had available baseline data for analysis. We observed that baseline PCFS score was statistically significantly positively correlated to baseline SHAPS score (β = 0.070, p = 0.045, 95% CI).
DISCUSSIONS: Our analysis revealed a significant relationship between measures of anhedonia and psychosocial functioning in adults with PCC. Strategies that aim to improve patient-reported outcomes with PCC need to prioritize the prevention and treatment of hedonic disturbances in patients experiencing PCC.
NEW MATERIAL:Lavendastine expressed by the formula (R is OH or H). USE:A bioactive substance having protein kinase-inhibiting activity and antitumor activity specific for tyrosine. Useful as biochemical reagent, antitumor agent or antibacterium agent. PREPARATION:Producing bacterium of lavendastine A (R=OH) or lavendastine B (R=H) belonged to genus Streptomyces is aerobically cultured in a medium containing optional nutrient source such as glycerin or glucose as carbon source and bean granule, cotton seed meal or meat extract as nitrogen source and a compound expressed by the formula is obtained from resultant cultured substance. An aerobic method in liquid deep part is suitable as a culturing method as well as popular production of antibiotic. Culturing temperature is 20-35 deg.C, preferably 25-30 deg.C.
Background and objectives: The impact of diabetes mellitus (DM) on the practice of peripheral nerve block anesthesia was mostly investigated in animal researches, and effects on human models are required to be clarified. The investigators performed this study to explore whether the presence of DM would affect the outcomes of axillary brachial plexus blocks (ABPBs) in patients undergoing elective forearm and/or hand surgery. The primary hypothesis was that the sensory block duration would be delayed in diabetic patients.

Methods: After obtaining ethics committee approval and written informed consent, 71 patients with American Society of Anesthesiologists (ASA) physical status I-III and aged between 40 and 75 years were enrolled to the study. Diabetic patients were included in Group DM and non-diabetics were included in Group NODM. All received ultrasound-guided ABPBs with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%. Postoperatively, patients were administered paracetamol as rescue analgesics, if numeric rating scale (NRS) was ≥4. Our primary outcome was sensory block duration, and secondary outcomes were sensory and motor block onset times, motor block duration, time-to-first-pain (numeric rating scale (NRS) ≥4), postoperative NRS scores, and rescue analgesic consumption (NRS) ≥4) through the postoperative first 2 days. All outcomes were assessed by a blinded investigators.
Schulte Grid digital game group will be asked to practice Schulte Grid digital game on the system for approximately 25 minutes/day at least 5 days a week. Compliance will be monitored electronically.
In the interventional group, patients receive 12 weeks of a remote physiotherapy via Akina Cloud in addition to conventional physiotherapy (treatment according to FMH Switzerland guidelines). Patients are encouraged to complete at least three app-guided training sessions per week.
A method and system for computing blood flow in coronary arteries from medical image data disclosed. Patient-specific anatomical measurements of a coronary artery tree are extracted from medical image data of a patient. A reference radius is estimated for each of a plurality of branches in the coronary artery tree from the patient-specific anatomical measurements of the coronary artery tree. A flow rate is calculated based on the reference radius for each of the plurality of branches of the coronary artery tree. A plurality of total flow rate estimates for the coronary artery tree are calculated. Each total flow rate estimate is calculated from the flow rates of branches of particular generation in the coronary artery tree. A total flow rate of the coronary artery tree is calculated based on the plurality of total flow rate estimates. The total flow rate of the coronary artery tree can be used to derive boundary conditions for simulating blood flow in the coronary artery tree.
PURPOSE:To obtain a lithoclastic agent producible easily, insertable easily in bored hole of a calculus, capable of breaking the calculus by dilation pressure and having high safety, by using a dilation material developing dilation pressure by the hydration reaction with water, ad kneading the agent with an organic solvent. CONSTITUTION:A dilation material developing dilation pressure by the hydration reaction with water (e.g. static disintegration agent, dilation material for cement concrete, quick lime, calcined dolomite, etc.) is kneaded with an organic solvent (e.g. methanol, ethyl ether, acetone, etc.) to obtain a solid lithoclastic agent easily. A lithoclastic agent having high handleability and insertable easily into the bored hole of a calculus can be formed by forming the dilation material in the form of rod, table, etc., using the organic solvent as a binder. Since the dilation pressure develops slowly according to the elapse of time, the calculus can be broken without generating gases and shock wave in contrast with the case using an explosive as a disintegration agent, and accordingly, the agent has excellent safety.